THEMIS MEDICARE LTD. - Receipt Of No Objection From The Drug Controller General Of India'S Office (Central Drug Control Authority ) For Manufacturing And Marketing A Key Product, I.E Diclofenac Injection 75Mg/Ml

Rediff Moneywiz

Hi Guest
Feedback

THEMIS MEDICARE LTD. - Receipt Of No Objection From The Drug Controller General Of India'S Office (Central Drug Control Authority ) For Manufacturing And Marketing A Key Product, I.E Diclofenac Injection 75Mg/Ml

Download	< Back
17 Feb 2023
With reference to our earlier disclosure dated 12th July, 2018 followed by our updates dated 08th July, 2019and 27th July, 2019, we have to now inform you that the Central Licensing Authority has conveyed its no objection to the Company for manufacturing and marketing a key product, i.e Diclofenac Injection 75mg/ml which the Company had stopped manufacturing and marketing pursuant to a directive from the State Food and Drug Administration authorities. The Company now proposes to examine various options to commercialise the said product and also deal with the pending litigation in consultation with its Legal Advisors. This is for your information and record.
View all announcements for THEMIS MEDICARE LTD.	Source: BSE India

ALL MONEYWIZ PAGES